Paragon Care Limited (PGC) AI Stock Analysis

• Market Cap: €653.85M
• Dividend Yield: N/A
• Average Volume (3M): 602.40K
• Price to Earnings (P/E): 31.6
• Beta (1Y): 1.03
• Revenue Growth: 1387.97%
• EPS Growth: -1.57%
• Country: AU
• Employees: 400
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Distribution
• EPS (TTM): 0.80
• Shares Outstanding: 1,655,305,400
• 10 Day Avg. Volume: 911,201
• 30 Day Avg. Volume: 602,405
• PEG Ratio: 1.16
• Price to Book (P/B): 2.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -246.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.53
• Price Target Upside: 38.70% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 63 Neutral
• Price Target: AU$0.50 ▲(31.58%Upside)

Paragon Care Limited's overall score reflects its strong financial performance and effective cash flow management. However, profitability challenges and a high P/E ratio weigh on the valuation. Technical analysis shows mixed signals, suggesting caution as the stock faces resistance. The absence of significant earnings call insights or corporate events means reliance is primarily on core financials and market trends.

Paragon Care Limited Business Overview & Revenue Model

Company Description

Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.

How the Company Makes Money

Paragon Care Limited generates revenue through the sale of medical equipment, devices, and consumables to hospitals, healthcare providers, and other medical institutions. The company also offers maintenance and support services for its products, providing an additional revenue stream. Key revenue streams include direct sales of their diverse range of healthcare products, long-term supply contracts, and partnerships with leading international manufacturers, which enable Paragon Care to distribute high-quality, innovative products across the Asia-Pacific region. The company's strategic acquisitions and partnerships help expand its product offerings and market reach, contributing significantly to its financial performance.

Paragon Care Limited Financial Statement Overview

Summary

Paragon Care Limited demonstrates a solid financial performance with consistent revenue growth and effective cash flow management. While the company faces some profitability challenges, its balanced leverage and cash generation capabilities provide a stable foundation for future growth.

Income Statement

Paragon Care Limited has shown a stable revenue growth trajectory over recent years with a revenue increase in the TTM period. Despite a dip in net income, the company maintains solid profit margins with a Gross Profit Margin of 5.93% and an EBIT Margin of 1.63% in the latest annual report. However, the decline in EBITDA and net income in the latest TTM period suggests profitability challenges remain.

Balance Sheet

The company demonstrates a moderate Debt-to-Equity Ratio of 0.86, reflecting a balanced leverage level. A positive Return on Equity of 2.87% indicates effective use of equity, albeit lower compared to previous periods. The Equity Ratio is 25.81%, showing a stable financial structure with room for improvement.

Cash Flow

Paragon Care Limited has exhibited strong cash flow management with significant Free Cash Flow growth, albeit from a negative base in the previous year. The Operating Cash Flow to Net Income ratio of 5.30 indicates strong cash generation relative to accounting profit, enhancing financial flexibility.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
4.66B	2.97B	307.63M	237.62M	235.84M	231.69M
	Gross Profit
230.97M	176.07M	51.68M	36.58M	33.41M	78.76M
	EBIT
63.76M	28.44M	26.41M	15.34M	13.98M	4.08M
	EBITDA
75.74M	43.18M	37.07M	23.27M	20.18M	-62.09M
	Net Income Common Stockholders
18.67M	8.38M	10.76M	6.63M	8.28M	-77.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
21.66M	19.94M	22.60M	46.20M	33.20M	24.50M
	Total Assets
1.24B	1.13B	448.52M	438.44M	291.92M	292.17M
	Total Debt
299.90M	251.83M	122.14M	131.26M	113.01M	115.03M
	Net Debt
278.24M	231.88M	99.54M	85.06M	79.81M	90.52M
	Total Liabilities
927.81M	838.97M	196.56M	196.31M	170.40M	179.89M
	Stockholders Equity
310.96M	291.92M	242.85M	235.82M	121.52M	112.28M
Cash Flow		Free Cash Flow
-2.93M	25.14M	-3.30M	14.42M	22.18M	-1.98M
	Operating Cash Flow
2.38M	44.45M	17.75M	19.03M	27.46M	5.29M
	Investing Cash Flow
-3.77M	-19.52M	-31.75M	7.07M	-18.80M	-11.40M
	Financing Cash Flow
12.93M	-5.95M	-10.00M	-11.93M	32.00K	-3.60M

Paragon Care Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PGC, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.40, and below the 200-day MA of 0.45, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.37 is Neutral, neither overbought nor oversold. The STOCH value of 48.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PGC.

Paragon Care Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGC	63 Neutral	€653.85M	31.60	6.68%	―	1387.97%	-1.57%
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%
ANSLF		$2.97B	22.01	6.45%	2.46%	―	―
CHEOF		$11.40B	48.88	20.61%	1.54%	―	―
CMXHF		$77.53B	27.88	15.38%	1.75%	―	―
RMSYF		$5.64B	1,067.27	0.52%	2.22%	―	―
SHL	72 Outperform	AU$12.78B	23.22	6.86%	4.02%	10.15%	6.20%

Paragon Care Limited Corporate Events

Paragon Care Limited Updates Securities Trading Policy

Paragon Care Limited has announced a revision to its Securities Trading Policy, aligning with ASX Listing Rule 12.10. This update reflects the company’s commitment to maintaining robust corporate governance practices. The revised policy is accessible on the company’s website, underscoring Paragon Care’s dedication to transparency and regulatory compliance, which is crucial for its stakeholders and market positioning.

Paragon Care Appoints New Independent Non-Executive Director

Paragon Care Limited has appointed Peter Egglestone as an independent Non-Executive Director, effective 20 March 2025. With over 25 years of leadership, financial, and commercial experience, Egglestone’s expertise is expected to be a valuable asset as the company continues to execute its strategic initiatives and strengthen its market position.

Paragon Care Director Increases Stake with Share Acquisition

Paragon Care Limited announced a change in the director’s interest, with Director Carmen Riley acquiring 100,000 additional ordinary shares through an on-market trade, bringing her total to 300,000 ordinary shares. This acquisition reflects a significant increase in personal investment by a key company leader, potentially indicating confidence in the company’s future prospects and stability, which may positively influence stakeholder perceptions.

Paragon Care Announces Leadership Transition as Part of Growth Strategy

Paragon Care Limited announced that Mr. John Walstab will transition from his executive role to a Non-Executive Director position effective 1 April 2025. Mr. Walstab, who founded Quantum Healthcare and played a key role in its merger with Paragon Care, will continue to contribute his expertise to the company’s board. This transition is part of Paragon Care’s strategy to integrate CH2 and ParagonCare, enhancing its growth prospects in the Asia-Pacific region.